ST. LOUIS (BusinessWire EON) February 12, 2007 --GenoMed® (OTC Pink Sheets GMED), a NextGeneration Disease Management company, announced today that it has foundthe “African gene,”responsible for the much higher incidence of diabetes, high bloodpressure, and kidney failure among people of African ancestry thanwhites.
High blood pressure, and many other diseases, are roughly twice ascommon among African Americans than whites. For people with high bloodpressure, kidney failure is five times more common among AfricanAmericans than whites. So blacks have 10 times more kidney failure thanwhites. The difference has been ascribed to the "African gene."
The “African gene,”or more accurately, “African genotype,”is actually a misnomer. It is not unique to Africans, but is present inevery ethnic group, where it appears to cause most common diseases. (Itis just more frequent among Africans). For example, it is associatedwith three-quarters of common diseases among whites. GenoMed has shownthat knowing this "master" disease gene makes it possible to preventkidney failure in whites, blacks, and Hispanics.
Said Dr. David Moskowitz, GenoMed’s CEO, “Itis appropriate that this February, Black History Month, we start tryingto make kidney dialysis a thing of the past, since African Americansdisproportionately make up the rolls of dialysis companies. So do otherpeople of color: Hispanics and Native Americans have much more diabetesand kidney failure than whites.”
Dr. Moskowitz continued, "The advantage of knowing the gene behind mostcommon diseases is obvious. In this case, society is fortunate toalready have safe, effective, cheap generic drugs that work against thegene. Our only problem for the past five years has been in getting theword out.”
Dr. Moskowitz has published extensively on the African gene inpeer-reviewed medical journals beginning in 1996.
About GenoMed
GenoMed estimates that it can already save 10% of healthcare costs andextend life by 5 years. Patients are encouraged to contact Dr. Moskowitz(dwmoskowitz@genomed.com)about joining GenoMed's Clinical Outcomes Improvement Program (COIP®).
Safe Harbor Statement
This press release contains forward-looking statements, including thosestatements pertaining to GenoMed, Inc.'s (the Company's) finances andtreatments. The words or phrases "ought to," "should," "could," "may,"or similar expressions are intended to identify "forward-lookingstatements" within the meaning of the Private Securities LitigationReform Act of 1995. Actual results could differ materially from thoseprojected in the forward-looking statements as a result of a number ofrisks and uncertainties, including but not limited to our research anddevelopment being subject to scientific, economic, regulatory,governmental, and technological factors. Statements made herein are asof the date of this press release and should not be relied upon as ofany subsequent date. Unless otherwise required by applicable law, wespecifically disclaim any obligation to update any forward-lookingstatements to reflect occurrences, developments, unanticipated events orcircumstances after the date of such statement.
xmlns:dc="http://purl.org/dc/elements/1.1/"xmlns:trackback="http://madskills.com/public/xml/rss/module/trackback/">rdf:about="http://www.prweb.comhttp://prweb.com/releases/african/genomed/prweb504552.htm"dc:identifier="http://www.prweb.comhttp://prweb.com/releases/african/genomed/prweb504552.htm"trackback:ping="http://www.prweb.com/postback/pingpr.php/VGhpci1DcmFzLUNvdXAtSG9yci1NYWduLVplcm8=" />-->
Post Comment:Trackback URL: http://www.prweb.com/chachingpr.php/VGhpci1DcmFzLUNvdXAtSG9yci1NYWduLVplcm8=
